Low Molecular Weight Heparins in Special Populations

Journal of Infusion Nursing

Volumn 26, Issue 5, 2003, Pages 304-310

  Howard, Patricia A ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARDEPARIN; BLOOD CLOTTING FACTOR 10A; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; TINZAPARIN; ANTICOAGULANT AGENT;

ANTICOAGULANT THERAPY; BLEEDING; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DOSE CALCULATION; DOSE KIDNEY FUNCTION RELATION; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG SAFETY; HUMAN; KIDNEY DYSFUNCTION; OBESITY; PREGNANCY; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; THROMBOEMBOLISM; FEMALE; KIDNEY DISEASE; NURSING; PREGNANCY COMPLICATION;

ANTICOAGULANTS; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; KIDNEY DISEASES; OBESITY; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; THROMBOEMBOLISM;

EID: 0141940778     PISSN: 15331458     EISSN: None     Source Type: Journal    
DOI: 10.1097/00129804-200309000-00006     Document Type: Review

References (48)

1. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low molecular weight heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy and safety. In: Dalen JE, Hirsh J, Guyatt GH, eds. Sixth ACCP Consensus Conference on Antithrombotic Therapy. Chest. 2001; 119(suppl):64S-94S.
2. Hirsh J, Levine MN. Low molecular weight heparin. Blood. 1992;79:1-17.
3. Weitz JI. Low molecular weight heparins. N Engl J Med 1997;337:688-698.
4. th ed. St. Louis: Facts and Comparisons; 2003.
5. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism, In: Dalen JE, Hirsh J, Guyatt GH, eds. Sixth ACCP Consensus Conference on Antithrombotic Therapy. Chest. 2001;119(suppl):132S-175S.
6. Hyers TM, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. In: Dalen JE, Hirsh J, Guyatt GH, eds. Sixth ACCP Consensus Conference on Antithrombotic Therapy. Chest. 2001; 119(suppl):176S-193S.
7. Cairns JA, Theroux P, Lewis HD, et al. Antithrombotic agents in coronary artery disease. In: Dalen JE, Hirsh J, Guyatt GH, eds. Sixth ACCP Consensus Conference on Antithrombotic Therapy. Chest. 2001;119(suppl):228S-252S.
8. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). Available at: http://www.acc.org/clinical/guidelines/unstable/unstable.pdf. Accessed January 21, 2003.
9. Antman EM, Cohen M, Radley D, et al for the TIMI 11B (Thrombolysis in Myocardial Infarction) and ESSENCE (Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events) Investigators. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction TIMI 11B-ESSENCE meta-analysis. Circulation. 1999;100:1602-1608.
10. Michalis LK, Papamichail N, Katsouras CS, et al. Enoxaparin versus tinzaparin in the management of unstable coronary artery disease (EVET Study) [abstract]. J Am Coll Cardiol. 2001;37:365A.
11. Klein W, Buchwald A, Hillis SE, et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC). Circulation. 1997;96:61-68. (Erratum appears in Circulation. 1998;97:413.)
12. Klein W, Buchwald A, Hillis SE, et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC). Circulation. 1997;96:61-68. (Erratum appears in Circulation. 1998;97:413.)
13. Boneu B, Moerloose de P. How and when to monitor a patient treated with low molecular weight heparin. Semin Thromb Hemost. 2001;27:519-522.
14. Duplaga BA, Rivers CW, Nutescu E. Dosing and monitoring of low-molecular weight heparins in special populations. Pharmacotherapy. 2001;21:218-234.
15. Albada J, Nieuwenhuis HK, Sixma JJ. Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Circulation. 1989;80:935-940.
16. Nieuwenhuis HK, Albada J, Banga JD, et al. Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. Blood. 1991;78:2337-2343.
17. a inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. Am Heart J. 2002;143:753-759.
18. Greaves M. Limitations of the laboratory monitoring of heparin therapy. Scientific and Standardization Committee Communications: on behalf of the Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis. Thromb Haemost. 2002;87:163-164.
19. Goudable C, Saivin S, Houin G, et al. Pharmacokinetics of a low molecular weight heparin (Fraxiparine) in various stages of chronic renal insufficiency. Nephron. 1991;59:543-545.
20. Cadroy Y, Pourrat J, Baladre MF, et al. Delayed elimination of enoxaparin in patients with chronic renal insufficiency. Thromb Res. 1991;63:385-390.
21. Sanderlink GJ, Guimart CG, Ozoux ML, et al. Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thromb Res. 2002;105:225-231.
22. a and anti-IIa activity over 10 days. Thromb Haemost. 2000;84:800-804.
23. Gerlach AT, Pickworth KK, Seth SK, et al. Enoxaparin and bleeding complications: a review in patients with and without renal insufficiency. Pharmacotherapy. 2000;20:771-775.
24. Inverso SM, Cohen M, Antman EM, et al. Safety and efficacy of unfractionated heparin (UH) versus enoxaparin (E) in obese patients and patients with renal impairment: Analysis from ESSENCE and TIMI 11B studies. J Am Coll Cardiol. 2001;37 (supp A): 365A.
25. Nagge J, Crowther M, Hirsh J. Is impaired renal function a contraindication to the use of low-molecular weight heparin? Arch Intern Med. 2002;162:2605-2609.
26. Collet JP, Montalescot G, Choussat R, et al. Enoxaparin in unstable angina patients with renal failure. Int J Cardiol. 2001;80:81-82.
27. Andrassy K, Eschenfelder V. Are the pharmacokinetics parameters of low molecular weight heparins predictive of their clinical efficacy? Thromb Res. 1996;81(suppl):S29-S38.
28. Yee JYV, Duffull SB. The effect of body weight on dalteparin pharmacokinetics. Eur J Clin Pharmacol. 2000;56:293-297.
29. Sanderink GJ, Liboux AL, Jariwala N, et al. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin Pharmacol Ther. 2002;72:308-318.
30. Hainer JW, Barrett JS, Assaid CA, et al. Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study. Thromb Haemost. 2002;87:817-823.
31. Grand'Maison A, Endrenyi L, MacLeod SM, et al. A population-based pharmacokinetic study of enoxaparin in obese patients with acute coronary syndrome [abstract]. Blood. 2001;98:43A.
32. Samama MM, Verhille C, Carchy L. Relation between weight, obesity and frequency of deep venous thrombosis after enoxaparin in orthopedic surgery [abstract]. Thromb Haemost. 1995;73:977.
33. Wilson SJ, Wilbur K, Burton E, Anderson DR. Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular-weight heparin for the treatment of venous thromboembolism. Haemostasis. 2001;31:42-48.
34. Toglia MR, Weg JG. Current concepts. VTE during pregnancy. N Engl J Med. 1996;335:108-114.
35. Greer IA. Exploring the role of low-molecular-weight heparins in pregnancy. Semin Thromb Hemost. 2002;28(suppl 3):25S-31S.
36. McColl MD, Ramsay JE, Tait RC, et al. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost. 1997;78:1183-1188.
37. Pettila V, Kaaja R, Leinonen P, et al. Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy. Thromb Res. 1999;96:275-282.
38. Nelson-Piercy C, Letsky EA, de Swiet M. Low-molecular weight heparin for obstetric thromboprophylaxis: experience of sixty-nine pregnancies in sixty-one women at high risk. Am J Obstet Gynecol. 1997;176:1062-1068.
39. Ellison J, Walker ID, Greer IA. Antenatal use of enoxaparin for the prevention and treatment of thromboembolism in pregnancy. Br J Obstet Gynaecol. 2000;107:1116-1121.
40. Lepercq J, Conard J, Borel Derlon A, et al. Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. Br J Obstet Gynaecol. 2001;108:1134-1140.
41. Sanson BJ, Lensing AW, Prins MH, et al. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost. 1999;81:668-672.
42. Ensom MHH, Stephenson MD. Low-molecular weight heparins in pregnancy. Pharmacotherapy. 1999;19:1013-1025.
43. Ginsberg JS, Greer I, Hirsh J. Use of antithrombotic agents during pregnancy. In: Dalen JE, Hirsh J, Guyatt GH, eds. Sixth ACCP Consensus Conference on Antithrombotic Therapy. Chest. 2001;119(suppl):122S-131S.
44. Casele HL, Laifer SA, Woelkers DA, et al. Changes in the pharmacokinetics of the low molecular weight heparin enoxaparin sodium during pregnancy. Am J Obstet Gynecol. 1999;181:1113-1137.
45. O'Shea SI, Ortel TL. Issues in the utilization of low molecular weight heparins. Semin Hematol. 2002;39:172-178.
46. AGOC Committee Opinion: safety of Lovenox in pregnancy. Obstet Gynecol. 2002;100(4):845-846.
47. Aggarwal M. Use of low-molecular-weight heparin in pregnant women with mechanical valves [letter]. Mayo Clin Proc. 2002;77:1133-1134.
48. Wu CL. Regional anesthesia and anticoagulation. J Clin Anesth. 2001;13:49-58.